搜索
ProQR Therapeutics NV
PRQR添加自选
1.810USD
+0.060+3.43%
收盘 07/02, 16:00（美东）报价延迟15分钟
194.96M总市值
亏损市盈率 TTM
关于 ProQR Therapeutics NV 公司
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV简介
公司代码PRQR
公司名称ProQR Therapeutics NV
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
员工数量166
证券类型Ordinary Share
年结日Sep 18
公司地址Zernikedreef 9
城市LEIDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Netherlands
邮编2333 CK
电话31881667000
网址https://www.proqr.com/
公司代码PRQR
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
ProQR Therapeutics NV公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
常见问题
ProQR Therapeutics NV的前五大股东是谁？
ProQR Therapeutics NV 的前五大股东如下：Mr. Gerard Platenburg, Ph.D.
有多少机构持有ProQR Therapeutics NV(PRQR)的股份？
截至2026Q1，共有122家机构持有ProQR Therapeutics NV的股份，合计持有的股份价值约为38.34M，占公司总股份的36.39%。与2025Q4相比，机构持股有所增加，增幅为-5670621.00。